NCT06059391View on ClinicalTrials.gov

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

PHASE2RecruitingINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

July 12, 2024

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2029

Conditions
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaChronic Myeloid Leukemia, BCR-ABL1 PositiveHematopoietic and Lymphoid System NeoplasmHodgkin LymphomaMyelodysplastic SyndromeMyelofibrosisMyeloproliferative NeoplasmNon-Hodgkin Lymphoma
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo HCT with donor peripheral blood stem cells

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Granulocyte Colony-Stimulating Factor

Undergo stem cell mobilization with G-CSF

DRUG

Hematopoietic Cell Transplantation Conditioning Regimen

Receive pre transplant conditioning

BIOLOGICAL

Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

Given IM

PROCEDURE

Pheresis

Undergo apheresis

DRUG

Placebo Administration

Given IM

DRUG

Stem Cell Mobilization Therapy

Undergo stem cell mobilization with G-CSF

Trial Locations (3)

30342

RECRUITING

Northside Hospital, Atlanta

91010

RECRUITING

City of Hope Medical Center, Duarte

02115

RECRUITING

DFCI/BWH Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER